AIM ImmunoTech is trading at $0.18, up 5.09%; available evidence does not establish a clear catalyst. - In an October 1 announcement, the company highlighted media coverage of Ampligen’s pancreatic-cancer strategy and progress in the Phase 2 DURIPANC trial. - AIM said final dosing is complete, with topline results expected in Q1 2027; the release did not connect the announcement to the share-price move. - Major indexes were modestly lower.